VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb 13, 2013) - Verisante Technology, Inc. (TSX VENTURE:VRS)(VRSEF)(V3T.F) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that Verisante Aura™, a revolutionary skin cancer detection device, has been named a 2013 finalist by the internationally renowned Edison Awards™. The distinguished awards symbolize the persistence and excellence personified by Thomas Alva Edison, inspiring creative minds to remain in the forefront of innovation, creativity and ingenuity in the global economy.
"More than we have seen at any other time previously, this year''s slate of finalists demonstrate the enormous value of teamwork, experimentation, consumer focus, market awareness and game-changing success," said Frank Bonafilia, Edison Awards'' executive director. "It''s exciting to see companies like Verisante continuing Thomas Edison''s legacy of challenging conventional thinking."
"It is an honour to be selected as an Edison Awards finalist," said Thomas Braun, President & CEO of Verisante. "Aura™ is a game-changing innovation that will significantly improve patient outcomes and care. It has taken some of the field''s brightest minds and years of research and commitment to bring this technology to commercialization."
The ballot of nominees for the Edison Awards is judged by more than 3,000 senior business executives and academics from across the nation whose votes acknowledge the finalists'' success in meeting the award criteria of Concept, Value, Delivery and Impact. The panel includes members of the Marketing Executives Networking Group (MENG), the American Association Advertising Agencies (4As), the Chief Marketing Officer Council (CMO), the Design Management Institute (DMI), the American Productivity & Quality Center (APQC), the American Society of Mechanical Engineers (ASME) and the Association of Technology Management & Applied Engineering (ATMAE). Also on the panel are hundreds of past Edison Award winners, marketing professionals, scientists, designers, engineers and academics.
Award winners will be announced April 25, 2013 at the Edison Awards Annual Gala, held in the Grand Ballroom at historic Navy Pier in Chicago, IL.
About the Edison Awards
The Edison Awards is a program conducted by Edison Universe, a 501(c)(3) charitable organization dedicated to fostering future innovators. The 2013 Edison Awards are sponsored by Nielsen, Discovery Communications, Science Channel, and USA Today. For more information about the Edison Awards, Edison Universe and a list of past winners, visit www.edisonawards.com.
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was awarded Popular Science Magazine''s "Best of What''s New Award" for 2011, and awarded a 2013 Prism Award for Innovation in Photonics. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.